Long-term treatment with probucol improves endothelial function in patients with coronary artery disease

Hypertension Research

Volumn 27, Issue 5, 2004, Pages 311-318

  Tagawa, Tatsuya ^b   Urabe, Yoshitoshi ^a   Kimura, Yoshikuni ^a   Suzuki, Satoshi ^a   Ono, Hiroki ^a   Takeda, Kotaro ^a  

^a KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Antioxidant; Coronary artery disease; Endothelial function

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRATE; PLACEBO; PROBUCOL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPEREMIA; LONG TERM CARE; MALE; PREDICTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PROBUCOL; TUNICA INTIMA; TUNICA MEDIA; VASODILATION;

EID: 3042545282     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.311     Document Type: Article

References (51)

1. Ross R: Rous-Whipple Award Lecture: atherosclerosis: a defense mechanism gone away. Am J Pathol 1993; 143: 987-1002.
2. Anderson TJ, Gerhard MD, Meredith IT, et al: Systemic nature of endothelial function in atherosclerosis. Am J Cardiol 1995; 75: 71B-74B.
3. Vanhoutte PM: Endothelial dysfunction and atherosclerosis. Eur Heart J 1997; 18(Suppl E): E19-E29.
4. Celermajer DS: Endothelial dysfunction: does it matter?: is it reversible? J Am Coll Cardiol 1997; 30: 325-333.
5. Drexler H: Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39: 287-324.
6. Shimokawa H: Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999; 31: 23-37.
7. Tagawa T, Hirooka Y, Shimokawa H, et al: Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 2002 ; 25: 823-829.
8. Leung WH, Lau CP, Wong CK: Beneficial effects of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-1500.
9. Egashira K, Hirooka Y, Kai H, et al: Reduction of serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
10. Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Eng J Med 1995; 332: 481-487.
11. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
12. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelium function within 1 month. Circulation 1997; 95: 1126-1131.
13. Dupuis J, Tardif JC, Cernacek P, et al: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial. Circulation 1999; 99: 3227-3233.
14. Takemoto M, Liao JK: Pleiotrophic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
15. Masumoto A, Hirooka Y, Hironaga K, et al: Effects of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-1294.
16. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57: 29H-35H.
17. Parthasarathy S, Young SG, Witztum JL, et al: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641-644.
18. Kuzuya, M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F: Probucol prevents oxidative injury to endothelial cell. J Lipid Res 1991; 32: 197-204.
19. Welch GN, Loscarzo J: Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
20. Moghadasian MH, McManus BM, Frohlich JJ: Homocyst(e)ine and coronary artery disease: clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157: 2299-2308.
21. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
22. Miyazaki H, Matsuoka H, Cooke JP, et al: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
23. Celermajer DS, Sorensen KE, Deanfield JE, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
24. Hashimoto M, Kozaki K, Eto M, et al: Association of coronary risk factors and endothelium-dependent flow-mediated dilatation of the brachial artery. Hypertens Res 2000; 23: 233-238.
25. Hirooka Y, Egashira K, Imaizumi T, et al: Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol 1994; 24: 948-955.
26. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A: Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in patients with coronary artery disease. J Cardiovasc Pharmacol 1999; 33: 633-640.
27. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T: Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000; 35: 71-75.
28. Halliwell B: Oxidative stress, nutrition and health: experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic Res 1996; 25: 57-74.
29. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
30. Berliner JA, Navab M, Fogelman AM, et al: Atherosclerosis: basic mechanisms: oxidation, inflammation and genetics. Circulation 1995; 91: 2488-2496.
31. Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 2000; 33 (Suppl): S85-S97.
32. Aviram M: Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Biochem 1996; 34: 599-608.
33. Steinberg D, Parthasarsthy S, Carew TK, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
34. Aviram M: Macrophage foam call formation during early atherogenesis is determined by the balance between pro-oxidants and antioxidants in arterial cells and in blood lipoproteins: a need for a dual approach. Antiox Redox Signal 1999; 1: 585-594.
35. Fuhrman B, Oiknine J, Aviram M: Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 1994; 111: 65-78.
36. Rosenblat M, Aviram M: Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: in vitro and in vivo studies. Free Radic Biol Med 1998; 24: 305-317.
37. Fuhrman B, Judith O, Keidar S, Ben-Yaish L, Kaplan M, Aviram M: Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic Biol Med 1997; 23: 34-46.
38. Lee YJ, Daida H, Yokoi H, et al: Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996; 37: 327-332.
39. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K: Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996; 132: 23-29.
40. Tardif JC, Cote G, Lesperance J, et al: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty: Multivitamins and Probucol Study Group. N Engl J Med 1997; 337: 365-372.
41. Rodes J, Cote G, Lesperance J, et al: Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998; 97: 429-436.
42. Cote G, Tardif JC, Lesperance J, et al: Effects of probucol on vascular remodeling after coronary angioplasty: Multivitamins and Protocol Study Group. Circulation 1999; 99: 30-35.
43. Celermajer DS, Sobey CG, Ryalls M, et al: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystiuria but not in their heterozygous patients. J Am Coll Cardiol 1993; 22: 854-858.
44. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121.
45. Vallance P, Leone AM, Calver A, Collier J, Moncada S: Accumulation of endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
46. Claver A, Collier J, Leone A, Moncada S, Vallance P: Effects of local intra-arterial asymmetric dimethylarginine (ADMA) on forearm arteriolar bed on healthy volunteers. J Hum Hypertens 1993; 7: 193-194.
47. Offord E, vanPoppel G, Tyrrell R: Markers of oxidative damage and antioxidant protection: current status and relevance to disease. Free Radic Res 2000; 33: S5-S19.
48. Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular disease. Free Radic Res 2000; 33: S85-S97.
49. Jeon SM, Bok SH, Jang MK, et al: Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. Clin Chim Acta 2002; 317: 181-190.
50. Imaeda A, Kaneko T, Aoki T, Kondo Y, Nagase H: DNA damage and the effects of antioxidants in streptozocin-treated mice. Food Chem Toxicol 2002; 40: 979-987.
51. Suzumura K, Ohashi N, Oka K, Yasuhara M, Narita H: Fluvastatin depresses the enhanced lipid peroxidation in vitamine E-deficient hamsters. Free Radic Res 2001; 35: 815-823.